30th EORTC-NCI-AACR SYMPOSIUM: Molecular Targets and Cancer Therapeutics
The 30th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics will be held Nov. 13-16 in Dublin, Ireland.
A press conference with dial-in facilities will take place at 12:30 p.m. ET/5:30 p.m. GMT on Tuesday, Nov. 13, Liffey room 2A, The Convention Centre, Dublin. This will include:
- Suggestions and navigational tips from the Symposium scientific co-chairs Charles Swanton, MD, PhD; James Gulley, MD, PhD; and Antoni Ribas, MD, PhD, for sessions and presentations during the Symposium that the scientific committee think may be of interest to journalists.
- Presentation by Laura van ’t Veer, PhD, of her new findings from the I-SPY 2 trial to be presented on Wednesday. Details of this are embargoed to the start of the scientific session in which she will make her presentation: 9:30 a.m. ET/2:30 p.m. GMT on Wednesday, Nov. 14.
If you want to join the press conference by telephone please email Gwydion Lyn: Gwydion.Lyn@ecco-org.eu (copying in Emma Mason/Kerry Noble: firstname.lastname@example.org) to register your interest and receive dial-in details.
There will be a full media program and there is still time for journalists to register online.
You will need to register to join the press conference even if you are unable to attend the Symposium in Dublin.
The media program will include:
- Latest results of the I-SPY 2 trial using genomic testing to identify breast cancer patients most likely to benefit from new drugs
- Results from a trial matching anti-cancer drugs to patients according to tumor genetic abnormality rather than type of cancer
- Results from a trial of a new oral drug to boost the effectiveness of radiotherapy for hard-to-treat cancers
- What is the effectiveness of a new anti-HER2 drug for treating cancers of the gullet, stomach, and bowel?
- The effect of combining immunotherapies to treat patients with non-small cell lung cancer
- Difficult-to-treat bowel cancer: how does it respond to a new combination of two immunotherapies?
- ”Significant” findings suggest effective, non-toxic treatment for aggressive childhood cancer
- New drug combination used to treat patients with rare, incurable cancers of the digestive tract
The European Organisation for Research and Treatment of Cancer (EORTC), the American Association for Cancer Research (AACR), and the National Cancer Institute (NCI) are joining forces for the Symposium where the latest advances in pre-clinical and clinical research will be presented. Around 1,500 international experts will be discussing innovations in drug development, target selection, and the impact of new discoveries in molecular biology.
For media queries about the Symposium, contact:
EORTC media consultants:
Tel: +44 (0)1376 563090
Mobile: +44 (0)7711 296 986
Mobile: +44 (0)7446 869 433
AACR media contact:
Mobile: +1 856 562 5668
More information on the program is available on the EORTC-NCI-AACR Symposium website.